Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ
Format:	Journal article
Wydane:	American Medical Association 2018

Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes od Lotta, L, Stewart, I, Sharp, S, Day, F, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, L, Kerrison, N, Khaw, K, McCarthy, M, O'Rahilly, S, Scott, R, Savage, D, Perry, J, Langenberg, C, Wareham, N

Wydane 2018

Journal article

Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

Podobne zapisy